NASDAQ:VCKA Vickers Vantage Corp. I (VCKA) Stock Price, News & Analysis → Jim Cramer’s “The Biggest Drug Ever” (From Behind the Markets) (Ad) Free VCKA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$8.77▼$10.5052-Week Range N/AVolume1,404 shsAverage Volume36,105 shsMarket Capitalization$118.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Vickers Vantage Corp. I alerts: Email Address Ad Behind the MarketsJim Cramer’s “The Biggest Drug Ever”This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.Unlock the details of this groundbreaking opportunity here... About Vickers Vantage Corp. IAs of November 10, 2022, Vickers Vantage Corp. I was acquired by Scilex Holding Company, in a reverse merger transaction. Vickers Vantage Corp. I does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Singapore.Read More Ad Behind the MarketsJim Cramer’s “The Biggest Drug Ever”This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.Unlock the details of this groundbreaking opportunity here... VCKA Stock News HeadlinesNovember 1, 2023 | morningstar.comRealty Income Corp OSeptember 8, 2023 | forbes.comClover Corp.April 26, 2024 | Behind the Markets (Ad)Jim Cramer’s “The Biggest Drug Ever”This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.July 8, 2023 | thestreet.comVickers Vantage Corp. I WarrantJune 26, 2023 | finance.yahoo.comKDKGF - Klondike Gold Corp.April 15, 2023 | entrepreneur.comSubchapter S CorporationFebruary 18, 2023 | marketwatch.com8-K: Lifevantage CorpFebruary 12, 2023 | investing.comVickers Vantage Corp I (VCKAU)April 26, 2024 | Behind the Markets (Ad)Jim Cramer’s “The Biggest Drug Ever”This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.January 29, 2023 | bizjournals.comKCI arises: Concessions manager aims to create 'extraordinary experience' for travelersNovember 15, 2022 | finance.yahoo.comThe Funded: Shares of Palo Alto's Scilex up 12% since it hit Wall Street in the Bay Area's 14th SPAC merger of 2022November 11, 2022 | seekingalpha.comShares of newly public biotech Scilex climb 5% following SPAC mergerAugust 24, 2022 | nasdaq.comVickers Vantage Corp. I Ordinary Shares (VCKA)August 17, 2022 | wsj.comVickers Vantage Corp. IJune 3, 2022 | seekingalpha.comSorrento's Scilex repurchases $41.4M notes ahead of going public with SPAC Vickers VantageJune 3, 2022 | finance.yahoo.comScilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured NotesSee More Headlines Receive VCKA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vickers Vantage Corp. I and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VCKA CUSIPN/A CIK1820190 Webwww.vickersvantage.com Phone646-974-8301FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-16.72% Return on Assets1.34% Debt Debt-to-Equity RatioN/A Current Ratio0.20 Quick Ratio1.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow374.61 Book Value($0.91) per share Price / BookN/AMiscellaneous Outstanding Shares13,176,000Free Float10,541,000Market Cap$118.72 million OptionableNot Optionable Beta0.03 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Chien-Chuen Chi C.F.A. (Age 54)Exec. Chairman & CEO Mr. Chris Ho (Age 33)CFO & Director Key CompetitorsCardiol TherapeuticsNASDAQ:CRDLaTyr PharmaNASDAQ:LIFEOmega TherapeuticsNASDAQ:OMGABioAtlaNASDAQ:BCABOutlook TherapeuticsNASDAQ:OTLKView All Competitors This page (NASDAQ:VCKA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressThe only accurate crypto trading system I know …Weiss RatingsThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vickers Vantage Corp. I Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.